Rosavin exerts an antitumor role and inactivates the MAPK/ERK pathway in small-cell lung carcinoma in vitro

Liu, Rui; Jiang, Cuihong; Zhao, Zhizheng; Lv, Yutong; Wang, Gaoxing

doi:10.2478/acph-2023-0015

Abstract

This study attempts to explore the function and mechanism of action of rosavin in small-cell lung cancer (SCLC) in vitro. The viability and clone formation of SCLC cells were assessed using cell counting kit-8 and colony formation assays, respectively. Apoptosis and cell cycle were detected using flow cytometry and cell cycle analysis, respectively. Wound healing and transwell assays were performed to evaluate the migration and invasion of SCLC cells. Besides, protein levels of p-ERK, ERK, p-MEK and MEK were determined using Western blot analysis. Rosavin repressed the viability and clone formation of SCLC cells, and promoted apoptosis and G₀/G₁ arrest of SCLC cells. At the same time, rosavin suppressed migration and invasion of SCLC cells. Moreover, protein levels of p-ERK/ERK and p-MEK/MEK were decreased after rosavin addition in SCLC cells. Rosavin impaired malignant behaviors of SCLC cells, which may be associated with inhibition of the MAPK/ERK pathway in vitro.

References

Y. Wang, S. Zou, Z. Zhao, P. Liu, C. Ke and S. Xu, New insights into small-cell lung cancer development and therapy, Cell Biol. Int. 44(8) (2020) 1564–1576; https://doi.org/10.1002/cbin.11359
Search in Google Scholar Back to article
A. Pavan, I. Attili, G. Pasello, V. Guarneri, P. F. Conte and L. Bonanno, Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges, J. Immunother. Cancer 7(1) (2019) Article ID 205 (13 pages); https://doi.org/10.1186/s40425-019-0690-1
Search in Google Scholar Back to article
F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre and A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, C. A. Cancer J. Clin. 68(6) (2018) 394–424; https://doi.org/10.3322/caac.21492
Search in Google Scholar Back to article
H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, C. A. Cancer J. Clin. 71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660
Search in Google Scholar Back to article
P. Goldstraw, Updated staging system for lung cancer, Surg. Oncol. Clin. N. Am. 20(4) (2011) 655–666; https://doi.org/10.1016/j.soc.2011.07.005
Search in Google Scholar Back to article
G. P. Kalemkerian, Small cell lung cancer, Semin. Respir. Crit. Care Med. 37(5) (2016) 783–796; https://doi.org/10.1055/s-0036-1592116
Search in Google Scholar Back to article
E. B. Bernhardt and S. I. Jalal, Small cell lung cancer, Cancer Treat. Res. 170 (2016) 301–322; https://doi.org/10.1007/978-3-319-40389-2_14
Search in Google Scholar Back to article
G. P. Kalemkerian and B. J. Schneider, Advances in small cell lung cancer, Hematol. Oncol. Clin. North Am. 31(1) (2017) 143–156; https://doi.org/10.1016/j.hoc.2016.08.005
Search in Google Scholar Back to article
S. Sundstrom, R. M. Bremnes, S. Kaasa, U. Aasebo, R. Hatlevoll, R. Dahle, N. Boye, M. Wang, T. Vigander, J. Vilsvik, E. Skovlund, E. Hannisdal, S. Aamdal and G. Norwegian, Lung cancer study: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up, J. Clin. Oncol. 20(24) (2002) 4665–4672; https://doi.org/10.1200/JCO.2002.12.111
Search in Google Scholar Back to article
M. Takada, M. Fukuoka, M. Kawahara, T. Sugiura, A. Yokoyama, S. Yokota, Y. Nishiwaki, K. Watanabe, K. Noda, T. Tamura, H. Fukuda and N. Saijo, Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104, J. Clin. Oncol. 20(14) (2002) 3054–3060; https://doi.org/10.1200/JCO.2002.12.071
Search in Google Scholar Back to article
R. L. Siegel, K. D. Miller, H. E. Fuchs and A. Jemal, Cancer statistics, 2021, C. A. Cancer J. Clin. 71(1) (2021) 7–33; https://doi.org/10.3322/caac.21654
Search in Google Scholar Back to article
T. F. Mott, Lung cancer: Management, F. P. Essent. 464 (2018) 27–30.
Search in Google Scholar Back to article
G. S. Jones and D. R. Baldwin, Recent advances in the management of lung cancer, Clin. Med. (Lond). 18(Suppl 2) (2018) s41-s46; https://doi.org/10.7861/clinmedicine.18-2-s41
Search in Google Scholar Back to article
C. Ma, J. Tang, H. Wang, G. Tao, X. Gu and L. Hu, Preparative purification of salidroside from Rhodiola rosea by two-step adsorption chromatography on resins, J. Sep. Sci. 32(2) (2009) 185–191; https://doi.org/10.1002/jssc.200800438
Search in Google Scholar Back to article
A. Kucinskaite, V. Briedis and A. Savickas, Experimental analysis of therapeutic properties of Rhodiola rosea L. and its possible application in medicine, Medicina (Kaunas) 40(7) (2004) 614–619.
Search in Google Scholar Back to article
Y. Li, J. Wu, R. Shi, N. Li, Z. Xu and M. Sun, Antioxidative effects of Rhodiola genus: Phytochemistry and pharmacological mechanisms against the diseases, Curr. Top. Med. Chem. 17(15) (2017) 1692–1708; https://doi.org/10.2174/1568026617666161116141334
Search in Google Scholar Back to article
S. N. Udintsev and V. P. Shakhov, Decrease in the growth rate of Ehrlich’s tumor and Pliss’ lymphosarcoma with partial hepatectomy, Vopr. Onkol. 35(9) (1989) 1072–1075.
Search in Google Scholar Back to article
H. Zhang, C. Ding, Y. Li, C. Xing, S. Wang, Z. Yu, L. Chen, P. Li and M. Dai, Data mining-based study of collagen type III alpha 1 (COL3A1) prognostic value and immune exploration in pan-cancer, Bioengineered 12(1) (2021) 3634–3646; https://doi.org/10.1080/21655979.2021.1949838
Search in Google Scholar Back to article
X. Xin, D. Yao, K. Zhang, S. Han, D. Liu, H. Wang, X. Liu, G. Li, J. Huang and J. Wang, Protective effects of rosavin on bleomycin-induced pulmonary fibrosis via suppressing fibrotic and inflammatory signaling pathways in mice, Biomed. Pharmacother. 115 (2019) Article ID 108870 (8 pages); https://doi.org/10.1016/j.biopha.2019.108870
Search in Google Scholar Back to article
W. X. Peng, J. G. Huang, L. Yang, A. H. Gong and Y. Y. Mo, Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer, Mol. Cancer 16(1) (2017) Article ID 161 (11 pages); https://doi.org/10.1186/s12943-017-0727-3
Search in Google Scholar Back to article
M. Pashirzad, R. Khorasanian, M. M. Fard, M. H. Arjmand, H. Langari, M. Khazaei, S. Soleiman-pour, M. Rezayi, G. A. Ferns, S. M. Hassanian and A. Avan, The therapeutic potential of MAPK/ERK inhibitors in the treatment of colorectal cancer, Curr. Cancer Drug Targets 21(11) (2021) 932–943; https://doi.org/10.2174/1568009621666211103113339
Search in Google Scholar Back to article
B. Wang, X. X. Zhu, L. Y. Pan, H. F. Chen and X. Y. Shen, PP4C facilitates lung cancer proliferation and inhibits apoptosis via activating MAPK/ERK pathway, Pathol. Res. Pract. 216(5) (2020) Article ID 152910; https://doi.org/10.1016/j.prp.2020.152910
Search in Google Scholar Back to article
Z. Wang, G. Kan, C. Sheng, C. Yao, Y. Mao and S. Chen, ARHGEF19 regulates MAPK/ERK signaling and promotes the progression of small cell lung cancer, Biochem. Biophys. Res. Commun. 533(4) (2020) 792–799; https://doi.org/10.1016/j.bbrc.2020.09.085
Search in Google Scholar Back to article
Y. Liu, Z. Zhang, T. Song, F. Liang, M. Xie and H. Sheng, Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2, Br. J. Pharmacol. 169(7) (2013) 1612–1623; https://doi.org/10.1111/bph.12243
Search in Google Scholar Back to article
S. Cristea and J. Sage, Is the canonical RAF/MEK/ERK signaling pathway a therapeutic target in SCLC?, J. Thorac. Oncol. 11(8) (2016) 1233–1241; https://doi.org/10.1016/j.jtho.2016.04.018
Search in Google Scholar Back to article
A. S. Marchev, P. Dimitrova, I. K. Koycheva and M. I. Georgiev, Altered expression of TRAIL on mouse T cells via ERK phosphorylation by Rhodiola rosea L. and its marker compounds, Food Chem. Toxicol. 108(Pt B) (2017) 419–428; https://doi.org/10.1016/j.fct.2017.02.009
Search in Google Scholar Back to article
R. Ruiz-Cordero and W. P. Devine, Targeted therapy and checkpoint immunotherapy in lung cancer, Surg. Pathol. Clin. 13(1) (2020) 17–33; https://doi.org/10.1016/j.path.2019.11.002
Search in Google Scholar Back to article
E. C. Naylor, J. K. Desani and P. K. Chung, Targeted therapy and immunotherapy for lung cancer, Surg. Oncol. Clin. N. Am. 25(3) (2016) 601–609; https://doi.org/10.1016/j.soc.2016.02.011
Search in Google Scholar Back to article
R. M. Montiel-Ruiz, M. E. Gonzalez-Trujano and M. Deciga-Campos, Synergistic interactions between the antinociceptive effect of Rhodiola rosea extract and B vitamins in the mouse formalin test, Phytomedicine 20(14) (2013) 1280–1287; https://doi.org/10.1016/j.phymed.2013.07.006
Search in Google Scholar Back to article
M. Deciga-Campos, M. E. Gonzalez-Trujano, R. Ventura-Martinez, R. M. Montiel-Ruiz, G. E. Angeles-Lopez and F. Brindis, Antihyperalgesic activity of Rhodiola rosea in a diabetic rat model, Drug Dev. Res. 77(1) (2016) 29–36; https://doi.org/10.1002/ddr.21289
Search in Google Scholar Back to article
Z. Liu, X. Li, A. R. Simoneau, M. Jafari and X. Zi, Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of auto-phagy, Mol. Carcinog. 51(3) (2012) 257–267; https://doi.org/10.1002/mc.20780
Search in Google Scholar Back to article
A. Majewska, G. Hoser, M. Furmanowa, N. Urbanska, A. Pietrosiuk, A. Zobel and M. Kuras, Anti-proliferative and antimitotic effect, S phase accumulation and induction of apoptosis and necrosis after treatment of extract from Rhodiola rosea rhizomes on HL-60 cells, J. Ethnopharmacol. 103(1) (2006) 43–52; https://doi.org/10.1016/j.jep.2005.05.051
Search in Google Scholar Back to article
X. Hu, S. Lin, D. Yu, S. Qiu, X. Zhang and R. Mei, A preliminary study: the anti-proliferation effect of salidroside on different human cancer cell lines, Cell Biol. Toxicol. 26(6) (2010) 499–507; https://doi.org/10.1007/s10565-010-9159-1
Search in Google Scholar Back to article
W. Zhang, W. Zhang, L. Huo, Y. Chai, Z. Liu, Z. Ren and C. Yu, Rosavin suppresses osteoclasto-genesis in vivo and in vitro by blocking the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) and mitogen-activated protein kinase (MAPK) signaling pathways, Ann. Transl. Med. 9(5) (2021) Article ID 383 (14 pages); https://doi.org/10.21037/atm-20-4255
Search in Google Scholar Back to article

Rosavin exerts an antitumor role and inactivates the MAPK/ERK pathway in small-cell lung carcinoma in vitro

Abstract

Paradigm

My account